Director Cedars-Sinai Cancer Center
Cedars-Sinai Medical Center
Los Angeles, California, United States
Theodorescu has emerged as an international leader in translational cancer research. His pioneering application of computational biology led to the discovery of genes that drive bladder and other cancers, while providing novel biomarkers and therapeutic targets and the foundations for personalized/precision therapeutic approaches such as the Molecular Twin Precision Oncology Platform (MT-POP) and the COXEN principle. He has led the discovery and development of a “first in class” RalGTPase inhibitor as a new therapeutic in several human cancer types (Nature 2014). His lab was the first to demonstrate that loss of the Y chromosome in cancer makes tumors more aggressive by allowing them to evade the immune system and that this advantage becomes a liability by increasing their sensitivity to immune checkpoint inhibitors which has broad implications in cancer medicine since many tumors lose the Y chromosome. His laboratory is currently funded by multiple federal grants. He has been elected to societies including the American Society for Clinical Investigation (ASCI), Association of American Physicians (AAP), the American Surgical Association (ASA) and the National Academy of Medicine (NAM). He is an Honorary Fellow of the American Association for the Advancement of Science (AAAS).
The Molecular Twin Artificial-Intelligence Platform in Precision Oncology
Thursday, November 21, 2024
11:00 AM – 11:45 AM PST